Publications by authors named "K Bunting"
Despite sharing ∼ 43 % sequence identity and structurally similar individual domains, botulinum neurotoxin (BoNT) serotypes A and E have differences in their properties and domain positioning. BoNT/E has a faster onset of action than BoNT/A. This difference is proposed to be due to conformational differences between BoNT/E and the other BoNT serotypes.
View Article and Find Full Text PDFBackground: Atrial fibrillation (AF) is a major and increasing burden on health services. This study aimed to evaluate the cost-effectiveness of digoxin versus beta-blockers for heart rate control in patients with permanent AF and symptoms of heart failure.
Methods: RAte control Therapy Evaluation in permanent Atrial Fibrillation (RATE-AF) was a randomised, open-label, blinded, endpoint trial embedded in the UK National Health Service (NHS) to directly compare low-dose digoxin with beta-blockers (ClinicalTrials.
Atrial fibrillation (AF) remains the most common cardiac arrhythmia worldwide and is associated with significant morbidity and mortality. The European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery (EACTS) have recently released the 2024 guidelines for the management of AF. This review highlights 10 novel aspects of the ESC/EACTS 2024 Guidelines.
View Article and Find Full Text PDFAn open source in silico workflow to assist in the design of fusion proteins.
Comput Biol Chem
December 2024
Fusion proteins have the potential to become the new norm for targeted therapeutic treatments. Highly specific payload delivery can be achieved by combining custom targeting moieties, such as V domains, with active parts of proteins that have a particular activity not naturally targeted to the intended cells. Conversely, novel drug products may make use of the highly specific targeting properties of naturally occurring proteins and combine them with custom payloads.
View Article and Find Full Text PDFArticle Synopsis
- This study investigates how gender affects decision-making for oral anticoagulation in patients with atrial fibrillation (AF), using a large dataset of over 16 million patients from UK primary care between 2005-2020.
- It found that in patients aged 40-75 without prior strokes, women had a lower adjusted rate of primary outcomes (death, ischemic stroke, or thromboembolism) compared to men, primarily due to lower mortality rates in women.
- The study concludes that omitting gender from clinical risk scores could streamline the process of determining which AF patients should receive oral anticoagulation.